Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder

Objective: To investigate the pharmacokinetics and pharmacodynamics of the approved 900/1,200 mg dosing regimen for the terminal complement component 5 (C5) inhibitor eculizumab in patients with neuromyelitis optica spectrum disorder (NMOSD). Methods: Data were analyzed from 95 patients with aquapor...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Pratap, Gao, Xiang, Kleijn, Huub Jan, Bellanti, Francesco, Pelto, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597263/
https://www.ncbi.nlm.nih.gov/pubmed/34803867
http://dx.doi.org/10.3389/fneur.2021.696387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597263/
https://www.ncbi.nlm.nih.gov/pubmed/34803867
http://dx.doi.org/10.3389/fneur.2021.696387

Ejemplares similares